Biocon Receives European Commission Approval for Breast Cancer Biosimilar Pebrilzo
Biocon Limited has received marketing authorisation from the European Commission for Pebrilzo, its pertuzumab biosimilar, to treat HER2-positive breast cancer across various stages in the EU. This approval follows a positive opinion from the European Medicines Agency and recent US FDA approval. Pebrilzo is the first biosimilar approved under the EMA's new tailored clinical approach and is indicated for use with trastuzumab and chemotherapy in early, locally advanced, inflammatory, and metastatic breast cancer cases.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (69/100). Lens Score 46/100.
Outlets measured: mint, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (68–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 18 Nov, 03:55 am. Other outlets followed.
- 1
